US 9,427,438 B2 · Compositions and methods for treating Alzheimer's disease

Abstract

The present invention provides compositions for reducing amyloid plaque burden associated with Alzheimer's disease and methods of using the same.

Claims6

Dependent claims

A method of treating a patient suffering from Alzheimer's Disease, the method comprising administering to the patient a pharmaceutical composition comprising VX-745.

Dependencies are inferred from the claim text.

Facts

Application

14/855,338Filed 15 Sep 2015 · continuation

Priority

9 May 2011

Published

US 2016/0030431 A14 Feb 2016

Granted

30 Aug 2016

Term ends

Not estimatedThe source records don’t support an estimate.

Classification21 codes

A61K 31/519
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim: ortho- or peri-condensed with heterocyclic rings
A61K 31/5025
Pyridazines; Hydrogenated pyridazines: ortho- or peri-condensed with heterocyclic ring systems
A61P 25/28
Drugs for disorders of the nervous system: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents,…
A61P 43/00
Drugs for specific purposes, not provided for in groups a61p1/00-a61p41/00

Family

Application61/483,919Us provisional application · filed 9 May 2011

Application13/467,519Parent of this continuation · filed 9 May 2012

Application14/191,984Parent of this continuation · filed 27 Feb 2014

US 8,697,627 B2Parent of this continuation · filed 15 Apr 2014

US 2016/0030431 A1Pre-grant publication · published 4 Feb 2016

US 2012/0289511 A1Published application

US 2014/0357638 A1Published application

US 9,427,438 B2This patent

From the US filing history. Foreign family members aren’t listed.

Abstract

The present invention provides compositions for reducing amyloid plaque burden associated with Alzheimer's disease and methods of using the same.

Facts

Application

14/855,338Filed 15 Sep 2015 · continuation

Priority

9 May 2011

Published

US 2016/0030431 A14 Feb 2016

Granted

30 Aug 2016

Term ends

Not estimatedThe source records don’t support an estimate.

Classification21 codes

A61K 31/519
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim: ortho- or peri-condensed with heterocyclic rings
A61K 31/5025
Pyridazines; Hydrogenated pyridazines: ortho- or peri-condensed with heterocyclic ring systems
A61P 25/28
Drugs for disorders of the nervous system: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents,…
A61P 43/00
Drugs for specific purposes, not provided for in groups a61p1/00-a61p41/00

Family

Application61/483,919Us provisional application · filed 9 May 2011

Application13/467,519Parent of this continuation · filed 9 May 2012

Application14/191,984Parent of this continuation · filed 27 Feb 2014

US 8,697,627 B2Parent of this continuation · filed 15 Apr 2014

US 2016/0030431 A1Pre-grant publication · published 4 Feb 2016

US 2012/0289511 A1Published application

US 2014/0357638 A1Published application

US 9,427,438 B2This patent

From the US filing history. Foreign family members aren’t listed.

Compositions and methods for treating Alzheimer's disease

Life of this patent

Abstract

Claims6

Compositions and methods for treating Alzheimer's disease

Life of this patent

Abstract

Claims6